94
Views
0
CrossRef citations to date
0
Altmetric
Letter

Are another 5 years of adjuvant aromatase inhibitor therapy needed?

, , &
Pages 207-209 | Published online: 14 Nov 2016

References

  • LeoneJLeoneBALeoneJPAdjuvant systemic therapy in older women with breast cancerBreast Cancer (Dove Med Press)2016814114727524919
  • YardleyDAPharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancerBreast Cancer (Dove Med Press)20168738227217795
  • BursteinHJLacchettiCAndersonHAdjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian SuppressionJ Clin Oncol201634141689170126884586
  • BursteinHJTeminSAndersonHAdjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused UpdateJ Clin Oncol201432212255226924868023
  • National Comprehensive Cancer Network (NCCN)NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 2.2016 Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdfAccessed October 25, 2016
  • GossPEIngleJNPritchardKIExtending aromatase-inhibitor adjuvant therapy to 10 yearsN Engl J Med2016375320921927264120
  • JerzakKJDesautelsDNPritchardKIAn update on adjuvant systemic therapy for elderly patients with early breast cancerExpert Opin Pharmacother201617141881188827539883

References

  • LeoneJLeoneBALeoneJPAdjuvant systemic therapy in older women with breast cancerBreast Cancer2016814114727524919
  • GossPEIngleJNPritchardKIExtending aromatase-inhibitor adjuvant therapy to 10 yearsN Engl J Med2016375320921927264120